8-K: Hepion Pharma Appoints Dr. Lbiati as CEO

Hepion Pharmaceuticals, Inc. announced the appointment of Dr. Kaouthar Lbiati as its new Chief Executive Officer, effective January 8, 2026, detailing her compensation and severance package.

Summary

• Dr. Kaouthar Lbiati has been appointed Chief Executive Officer of Hepion Pharmaceuticals, Inc., effective January 8, 2026.
• Her annual base salary is $350,000, with $50,000 deferred and payable upon specific conditions, including an equity financing of at least $3,000,000.
• She is eligible for an annual cash discretionary bonus targeting 35% of her base salary.
• A change of control bonus of 3.0% of the Enterprise Value is payable if the Enterprise Value equals or exceeds $5,000,000.
• The employment agreement outlines severance benefits for various termination scenarios, including accelerated vesting of equity awards.

Sentiment

Score: 6

Explanation: The appointment of a new CEO is generally a neutral to slightly positive event, indicating leadership continuity or a fresh start. The compensation package is standard for a public company CEO, with some incentives tied to capital raising and change of control, which could be seen positively for aligning interests. However, the deferred salary tied to a capital raise also hints at potential future financing needs, which could be a concern.

Positives

• The appointment of a new CEO could bring fresh leadership and strategic direction to the company.
• The deferred salary component tied to a minimum $3,000,000 equity financing aligns management incentives with capital raising efforts.
• The change of control bonus structure incentivizes the CEO to maximize shareholder value in potential acquisition scenarios.

Negatives

• Significant severance packages and accelerated vesting clauses could result in substantial costs for the company in certain termination events.
• The deferred salary component indicates a potential future need for capital raise, which could dilute existing shareholders if not executed favorably.

Risks

• Potential financial burden from severance payments and accelerated equity vesting if the CEO's employment is terminated without cause or for good reason.
• The company's ability to secure the minimum $3,000,000 equity financing to trigger the deferred salary payment is a future financial risk.
• The success of the company under new leadership is inherently uncertain and depends on Dr. Lbiati's strategic execution.

Future Outlook

The employment agreement includes provisions for a deferred salary component contingent on a future equity financing of at least $3,000,000, indicating a potential future capital raise.

Management Comments

• There are no arrangements or understandings between Dr. Lbiati and any other person pursuant to which she was selected as an officer of the Company.
• There is no family relationship between Dr. Lbiati and any of the Company's other directors or executive officers.

Industry Context

The appointment of a new CEO in a biotechnology or pharmaceutical company often signals a strategic shift or a renewed focus on clinical development and commercialization, especially given the specific financial incentives tied to capital raises and change of control events. This move could position Hepion Pharmaceuticals for new growth initiatives or a re-evaluation of its pipeline.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• **Shareholders:** Potential for new strategic direction under Dr. Lbiati's leadership. Compensation structure includes incentives for capital raise and change of control, potentially aligning with shareholder value creation. However, severance costs could impact shareholder value in certain scenarios.
• **Employees:** A new CEO may lead to organizational changes or new strategic priorities, potentially affecting employee morale or roles.

Next Steps

• Secure an equity financing of a minimum of $3,000,000 to trigger the payment of the CEO's deferred base salary.

Key Dates

Recommendation

The appointment of a new CEO is a significant event that can bring new direction, but without further details on Dr. Lbiati's specific strategic plans or the company's current financial performance, it is difficult to assess the immediate impact. The compensation structure, while standard, includes incentives tied to future capital raises and potential change of control, which introduces both opportunity and uncertainty. Investors should hold and await further strategic updates and financial disclosures under the new leadership.

Keywords

Hepion Pharmaceuticals, HEPA, CEO appointment, Kaouthar Lbiati, Executive Compensation, Employment Agreement, Corporate Governance, Biotechnology, Pharmaceuticals, SEC Filing, 8-K